Advertisement

Clinical Pharmacokinetics

, Volume 55, Issue 5, pp 637–639 | Cite as

Author’s reply to Veloso HH Comment on “The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm”

  • Roger W. JelliffeEmail author
Letter to the Editor
  • 103 Downloads

I thank Dr. Veloso for a most thoughtful letter [1] supporting my findings that digitalis glycosides are capable not only of converting patients with atrial fibrillation, and even chronic stable atrial flutter for 3 years, to regular sinus rhythm (RSR), but also of maintaining them in RSR for at least 2–4 weeks [2]. Hearing this is a real breath of fresh air after so many years of being isolated by the main community of cardiologists. Thank you also for the other references, which I had not been aware of. It certainly looks like a carefully thought out randomized trial should be conducted to study this issue further.

In my experience, medical schools worldwide have failed to incorporate modern pharmacokinetics into the education of medical students in any clinically meaningful way. As a result, most physicians all over the world have failed to become acquainted with modern pharmacokinetic knowledge. My experience at the yearly meetings of the American Heart Association in Chicago in...

Keywords

Atrial Fibrillation Digoxin Therapeutic Drug Monitoring Ventricular Rate Peripheral Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Funding

No external sources of funding were used in the preparation of this manuscript.

Conflicts of interest

Roger W. Jelliffe has no conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Veloso HH. Comment on: “The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to sinus rhythm”. Clin Pharmacokinet. 2016. doi: 10.1007/s40262-016-0380-9.
  2. 2.
    Jelliffe R. The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to sinus rhythm. Clin Pharmacokinet. 2014;53:397–407.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Falk R, Knowlton A, Bernard S, Gotlieb N, Battinelli N. Digoxin for converting atrial fibrillation to sinus rhythm: a random double-blinded trial. Ann Int Med. 1987;4:503–6.CrossRefGoogle Scholar
  4. 4.
    Bianconi L, Mennuni M, For the PATIF-3 Investigators. Comparison between propafenone and digoxin administered intravenously to patients with atrial fibrillation. Am J Cardiol. 1998;82:584–8.Google Scholar
  5. 5.
    Reuning R, Sams R, Notari R. Role of pharmacokinetics in drug dosage adjustment. 1. Pharmacologic effects, kinetics, and apparent volume of distribution of digoxin. J Clin Pharmacol. 1973;13:127–41.Google Scholar
  6. 6.
    Jelliffe R, Milman M, Schumitzky A, Bayard D, Van Guilder M. A two-compartment population pharmacokinetic–pharmacodynamic model of digoxin in adults, with implications for dosage. Ther Drug Monit. 2014;36(3):387–93.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    The USC Pmetrics and RightDose software. The only software with integrated pop modeling, simulation, and maximally precise dosage: Jelliffe R, Schumitzky A, Bayard D, Van Guilder M, Botnen A, Neely M, Thomson A, Bustad A. Laboratory of Applied Pharmacokinetics, USC Keck School of Medicine, Los Angeles (CA). A software demonstration at the Population Approach Group Europe, 11–14 June 2013, Glasgow, Scotland.Google Scholar
  8. 8.
    D’Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharmacol. 1981;9:739–56.CrossRefGoogle Scholar
  9. 9.
    Bayard D, Jelliffe R. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn. 2004;31(1):75–107.CrossRefPubMedGoogle Scholar
  10. 10.
    Macdonald I, Staatz C, Jelliffe R, Thomson A. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit. 2008;30:67–74.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Blom H. An efficient filter for abruptly changing systems. In: Proceedings of the 23rd conference on decision and control; Las Vegas (NV); 1984, pp. 656–8.Google Scholar
  12. 12.
    Blom H, Bar-Shalom Y. The interacting multiple model algorithm for systems with Markovian switching coefficients. IEEE Trans Autom Control. 1988;33:780–3.CrossRefGoogle Scholar
  13. 13.
    Mazor E, Averbuch A, Bar-Shalom Y, Dayan J. Interacting multiple model methods in target tracking: a survey. IEEE Trans Aerosp Electron Syst. 1998;34:103–23.CrossRefGoogle Scholar
  14. 14.
    Doherty J. Digitalis glycosides: pharmacokinetics and their clinical implications. Ann Int Med. 1973;79:229–38.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Professor of Medicine EmeritusUSC School of MedicineLos AngelesUSA
  2. 2.Founder and Director EmeritusLaboratory of Applied Pharmacokinetics and BioinformaticsLos AngelesUSA
  3. 3.Children’s Hospital of Los AngelesLos AngelesUSA

Personalised recommendations